Muh-Hwa Yang is a co-founder of Elixiron Immunotherapeutics. He currently serves as Vice President and Distinguished Professor of National Yang-Ming University, Adjunct Research Fellow of Genomic Research Center, Academia Sinica, Director of Medical Oncology, Taipei Veterans General Hospital, and Executive Director of Taiwan Oncology Society. Muh-Hwa is a clinician-scientist whose principal research interests are in the fields of cancer metastasis and stemness as well as developmental cancer therapeutics. He directs an active clinical practice in medical oncology specializing in the care of patients with head and neck cancer. Muh-Hwa has published over a hundred peer-reviewed manuscripts in the leading’s journals including Cancer Cell, Nature Cell Biology, and Oncogene. He has won numerous awards and honors for his research and holds several patents. Muh-Hwa received his M.D. and Ph.D. from National Yang Ming University and completed his residency of internal medicine and chief residency and clinical fellowship in Hematology-Oncology at Taipei Veterans General Hospital, Taiwan.